Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is scheduled to release its earnings data on Monday, October 30th. Analysts expect Zimmer Biomet Holdings to post earnings of $1.83 per share for the quarter.
Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($0.02). The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $2.02 earnings per share. On average, analysts expect Zimmer Biomet Holdings to post $8.23 EPS for the current fiscal year and $8.76 EPS for the next fiscal year.
Zimmer Biomet Holdings, Inc. (ZBH) opened at 124.46 on Friday. The stock has a 50 day moving average of $117.60 and a 200 day moving average of $120.39. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49. The stock has a market capitalization of $25.17 billion, a P/E ratio of 35.45 and a beta of 1.19.
The business also recently declared a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 22nd were paid a $0.24 dividend. The ex-dividend date was Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.
TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) to Release Earnings on Monday” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/zimmer-biomet-holdings-inc-zbh-to-release-earnings-on-monday.html.
In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.07% of the company’s stock.
ZBH has been the subject of a number of recent analyst reports. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BMO Capital Markets reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Morgan Stanley upped their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings currently has an average rating of “Hold” and an average target price of $136.55.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.